Professor Jake Shortt

Learn more about Monash Health’s Haematology team.

Professor Jake Shortt

BMedSc, Otago (Distinction); MB ChB, Otago (Distinction); FRACP; FRCPA; PhD, Melbourne.

Prof Jake Shortt is a clinical and laboratory Haematologist with subspecialty interests in malignant haematology – particularly leukaemia, lymphoma, myelodysplasia and myeloma. He is the clinical lead at Monash Health for chronic myeloid leukaemia, myelodysplasia and T-cell lymphoma and serves as a Principal Investigator on phase 1-4 clinical trials in these disease areas.

Prof Shortt is co-appointed to Monash University as the Head of Haematology Research within the Department of Medicine at the School of Clinical Sciences and is an Adjunct Clinical Professor at the University of Melbourne in the Sir Peter MacCallum Department of Oncology.

He heads the ‘Blood Cancer Therapeutics Laboratory’ in the Monash Health Translation Precinct, seeking to discover new blood cancer treatments and bring them to the clinic. His research program is supported by an NHMRC Investigator Grant and funding from the Cancer Council of Victoria (CCV) and the US Leukaemia and Lymphoma Society. His laboratory is also generously supported by philanthropic donations from the Bode Family and Dr Alexander Baxter.

Key recent publications (last 5 years)

Defeating MYC with drug combinations or dual-targeting drugs. Thompson PE & Shortt J. Trends Pharmacol Sci 2024; May 22:S0165-6147(24)00085-3

Mezigdomide in multiple myeloma. Shortt J. New Engl J Med 2023; 389: 1046-50.

Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma. Oh DH, Ma X, Hogg SJ, He J, Kearney J, Brasacchio D, Susanto O, Maher B, Jennings IG, Newbold A, Fraser P, Gruber E, Kats LM, Gregory GP, Johnstone RW, Thompson PE, Shortt J. Proc Natl Acad Sci USA 2023; 120(36): e2306414120.

A phase 1 clinical trial of the repurposable acetyl-lysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. Shortt J, Galettis P, Cheah CY, Davis J, Ludford-Menting M, Link EK, Martin JH, Koldej R, Ritchie D. Clin Epigenetics 2023; 15(1): 15.

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J. Leukemia 2022; 36: 1654-65.

Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP). Chen M & Shortt J. Transfus Med Rev 2022; 36: 204-14.

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Costacurta M, Vervoort SJ, Hogg SJ, Martin BP, Johnstone RW, Shortt J. Haematologica 2021; 106: 2013-17.

Our Emergency Departments are experiencing extreme demand. If your condition is urgent but not a medical emergency, please consider alternative care options.Learn more
+